PT2797581T - Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona - Google Patents

Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona

Info

Publication number
PT2797581T
PT2797581T PT128086626T PT12808662T PT2797581T PT 2797581 T PT2797581 T PT 2797581T PT 128086626 T PT128086626 T PT 128086626T PT 12808662 T PT12808662 T PT 12808662T PT 2797581 T PT2797581 T PT 2797581T
Authority
PT
Portugal
Prior art keywords
aminoisoindoline
methanesulfonyl
dione
ethoxy
acetyl
Prior art date
Application number
PT128086626T
Other languages
English (en)
Original Assignee
Amgen Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2797581(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Europe Gmbh filed Critical Amgen Europe Gmbh
Publication of PT2797581T publication Critical patent/PT2797581T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
PT128086626T 2011-12-27 2012-12-26 Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona PT2797581T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161580626P 2011-12-27 2011-12-27

Publications (1)

Publication Number Publication Date
PT2797581T true PT2797581T (pt) 2020-06-18

Family

ID=47459206

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128086626T PT2797581T (pt) 2011-12-27 2012-12-26 Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona

Country Status (33)

Country Link
US (2) US20130164376A1 (pt)
EP (2) EP3756650A1 (pt)
JP (1) JP6161629B2 (pt)
KR (3) KR102232154B1 (pt)
CN (1) CN104136003A (pt)
AU (1) AU2012362562B2 (pt)
BR (1) BR112014015923B1 (pt)
CA (1) CA2861594A1 (pt)
CL (1) CL2014001726A1 (pt)
CO (1) CO7000777A2 (pt)
CR (1) CR20140314A (pt)
CY (1) CY1123174T1 (pt)
DK (1) DK2797581T3 (pt)
EA (1) EA027801B1 (pt)
EC (1) ECSP14007965A (pt)
ES (1) ES2799448T3 (pt)
HK (1) HK1202056A1 (pt)
HR (1) HRP20200825T1 (pt)
HU (1) HUE050327T2 (pt)
IL (1) IL233296B (pt)
LT (1) LT2797581T (pt)
MX (2) MX2014007878A (pt)
NI (1) NI201400068A (pt)
PE (1) PE20142318A1 (pt)
PH (1) PH12014501495A1 (pt)
PL (1) PL2797581T3 (pt)
PT (1) PT2797581T (pt)
RS (1) RS60415B1 (pt)
SG (2) SG10201605251VA (pt)
SI (1) SI2797581T1 (pt)
UA (1) UA113750C2 (pt)
WO (1) WO2013101810A1 (pt)
ZA (1) ZA201404629B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2803524T3 (es) 2011-09-14 2021-01-27 Amgen Europe Gmbh Formulaciones de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida del ácido ciclopropanocarboxílico
EP3756650A1 (en) 2011-12-27 2020-12-30 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
US9994522B2 (en) 2014-05-11 2018-06-12 Mapi Pharma Ltd. Amorphous form of apremilast
EP3174999A1 (en) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
ES2871175T3 (es) * 2015-06-30 2021-10-28 Genentech Inc Comprimidos de liberación inmediata que contienen un fármaco y procesos para la formación de los comprimidos
CZ20165A3 (cs) * 2016-01-06 2017-07-19 Zentiva, K.S. Způsoby přípravy amorfního apremilastu
CN109310624A (zh) 2016-06-15 2019-02-05 托伦特药物有限公司 阿普斯特的局部组合物
AU2019443366A1 (en) * 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
ES2823927B2 (es) * 2019-11-07 2022-01-18 Beijing Enbiwo Biological Tech Co Ltd Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
KR20220047105A (ko) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 아프레밀라스트를 함유하는 약학 조성물
CN112245403B (zh) * 2020-10-23 2022-04-22 杭州朱养心药业有限公司 磷酸二酯酶-4抑制剂及其口服固体组合物
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023118043A1 (en) 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
JP4065567B2 (ja) 1996-07-24 2008-03-26 セルジーン コーポレイション 置換２―（２，６―ジオキソピペリジン―３―イル）フタルイミド類及び―１―オキソイソインドリン類ならびにＴＮＦαレベルの減少方法
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
JP2003513038A (ja) * 1999-10-29 2003-04-08 スミスクライン・ビーチャム・コーポレイション ホスホジエステラーゼ４阻害剤の投与法
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CN101966183A (zh) 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
JP2007533761A (ja) 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
WO2006053160A2 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
MX2007006063A (es) 2004-11-23 2007-07-11 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
ZA200704964B (en) 2004-12-01 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations
ES2526415T3 (es) * 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
WO2006111980A2 (en) 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
JP2009507030A (ja) 2005-09-01 2009-02-19 セルジーン・コーポレーション ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2196465A1 (en) * 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
PE20120580A1 (es) 2009-02-10 2012-05-23 Celgene Corp Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
CA2780941C (en) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
MX354210B (es) * 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
EP3756650A1 (en) 2011-12-27 2020-12-30 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Also Published As

Publication number Publication date
SG11201403564YA (en) 2014-07-30
CA2861594A1 (en) 2013-07-04
NZ626615A (en) 2016-08-26
CR20140314A (es) 2014-10-28
HUE050327T2 (hu) 2020-11-30
EP3756650A1 (en) 2020-12-30
RS60415B1 (sr) 2020-07-31
KR102232154B1 (ko) 2021-03-25
EA201491292A1 (ru) 2014-11-28
JP2015506356A (ja) 2015-03-02
MX2020005145A (es) 2020-08-17
PH12014501495B1 (en) 2014-09-22
LT2797581T (lt) 2020-07-10
SG10201605251VA (en) 2016-08-30
CY1123174T1 (el) 2021-10-29
EP2797581A1 (en) 2014-11-05
IL233296B (en) 2018-11-29
PE20142318A1 (es) 2015-01-16
NI201400068A (es) 2016-01-28
KR20140108707A (ko) 2014-09-12
PL2797581T3 (pl) 2020-10-05
US20210093573A1 (en) 2021-04-01
ECSP14007965A (es) 2015-11-30
HK1202056A1 (en) 2015-09-18
BR112014015923B1 (pt) 2022-02-01
WO2013101810A1 (en) 2013-07-04
BR112014015923A8 (pt) 2017-07-04
CO7000777A2 (es) 2014-07-21
ZA201404629B (en) 2017-08-30
CL2014001726A1 (es) 2014-11-14
AU2012362562A1 (en) 2014-07-17
KR20190120418A (ko) 2019-10-23
UA113750C2 (xx) 2017-03-10
JP6161629B2 (ja) 2017-07-12
KR102035362B1 (ko) 2019-10-22
CN104136003A (zh) 2014-11-05
BR112014015923A2 (pt) 2017-06-13
US20130164376A1 (en) 2013-06-27
KR20210033073A (ko) 2021-03-25
HRP20200825T1 (hr) 2020-08-07
DK2797581T3 (da) 2020-07-20
IL233296A0 (en) 2014-08-31
AU2012362562B2 (en) 2017-11-02
EA027801B1 (ru) 2017-09-29
PH12014501495A1 (en) 2014-09-22
ES2799448T3 (es) 2020-12-17
SI2797581T1 (sl) 2020-08-31
EP2797581B1 (en) 2020-05-06
MX2014007878A (es) 2015-03-23

Similar Documents

Publication Publication Date Title
HK1202056A1 (en) Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13-
HK1199255A1 (en) Indazole compounds, compositions and methods of use
EP2720631A4 (en) SURGICAL ALIGNMENT USING REFERENCES
IL230836A (en) Multi-part disinfectant system
SG10201605172RA (en) Compositions and methods for selectively etching titanium nitride
ZA201403969B (en) 2-(substituted-phenyl)=cyclopentane-1,3-dione compounds, and derivatives thereof
EP2796109A4 (en) DENTAL MEMBRANE
ZA201402148B (en) Coolant formulations
SI2753311T1 (sl) Formulacije antioksidanta
HRP20190186T1 (hr) Nove formulacije (trimetoksifenilamino)pirimidinila
GB201114725D0 (en) Ophthalmic formulations
HK1213785A1 (zh) 血管緊張素的口服製劑
EP2680774A4 (en) FLUORESCENT HANDPIECE
GB201110278D0 (en) Formulations
TH1401003680A (th) สูตรผสมของ (+)-2-[1-(3-อีธอกซิ-4-เมธอกซิ-ฟีนิล)-2-มีเธนซัลโฟนิล-เอธิล]-4- อะซิติลอะมิโนไอโซอินโดไลน์-1,3-ไดโอน
GB201111578D0 (en) Pharmeutical formulations
GB201111013D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201109725D0 (en) Push-pull outlet